Gialgan Fidia 20 mg/2ml syringe

Giallan Fidia – corrective metabolism of bone and cartilage tissue, analgesic, anti-inflammatory.

Pharmacodynamics

Hyalgan Fidia is a sterile, apyrogenic, viscous buffered aqueous solution of high purity sodium salt fraction of hyaluronic acid with a molecular weight of 500 to 730 kDa.

Hyaluronic acid is an essential component of the extracellular matrix and is present in high concentrations in articular cartilage and synovial fluid.

Endogenous hyaluronic acid provides viscosity and elasticity of synovial fluid, and it is also necessary for the formation of proteoglycans in articular cartilage. In osteoarthritis there are deficiencies and qualitative changes in hyaluronic acid in synovial fluid and cartilage.

Intra-articular injection of hyaluronic acid against degenerative changes of synovial cartilage surface and pathology of synovial fluid leads to improvement of functional state of the joint. When using Gialgan Fidia an improvement of clinical course of osteoarthritis during six months from the time of treatment is noted, anti-inflammatory and analgesic effect is observed.

Pharmacokinetics

The sodium salt of hyaluronic acid is eliminated from synovial fluid within 2-3 days when administered intra-articularly. Pharmacokinetic studies have shown rapid distribution of the substance in the synovial membrane. The highest concentrations of labeled hyaluronic acid were found in the synovial fluid and joint capsule, lower concentrations in the synovial membrane, ligaments and adjacent muscles.

Hyaluronic acid in synovial fluid undergoes no significant metabolic changes. In experimental models the main metabolism occurs in the periarticular tissues and the liver, the excretion is mainly by the kidneys.

Indications

Active ingredient

Composition

Active ingredient:

Sodium hyaluronate 20 mg;

Auxiliary substances:

sodium chloride;

diphosphate dodecahydrate;

sodium dihydrophosphate dihydrate;

water for injection;

How to take, the dosage

Intra-articularly. In knee and hip joints the contents of one vial (20 mg/2 ml) or filled syringe (20 mg/2 ml) should be injected once a week, a course of 5 injections according to the standard technique.

Injection technique

The effusion should be removed from the joint sac before Gialgan Fidia is injected. The drug should be injected precisely into the joint cavity according to standard techniques, taking into account the anatomical features.

The same needle, once inserted prior to aspiration, may be used to remove the effusion and administer the drug. In doing so, the syringe containing the medication is attached to the aspirated needle that has been freed from the aspirated syringe. To confirm the needle is in the joint cavity, aspirate the available amount of synovial fluid before slowly injecting the drug. Aseptics and antiseptics should be followed during the procedure.

Injection of the drug into the joint cavity should be stopped if pain occurs during the injection. Air should be avoided in the syringe containing the medication. Unused medication should not be stored.

Interaction

Gialgan Fidia should not be administered at the same time as other intra-articular injections, due to a lack of significant experience.

Do not use disinfectants containing quaternary ammonium salts because hyaluronic acid precipitates in the presence of these substances.

Special Instructions

During the first 2 days after the procedure it is recommended not to overload the joint, especially prolonged strain should be avoided. If aspiration fluid is obtained before the drug is administered, appropriate tests should be performed to rule out the bacterial etiology of arthritis.

Gialgan Fidia does not affect the person’s ability to drive vehicles, engage in other potentially dangerous activities requiring increased concentration and rapid psychomotor reactions.

Do not use the drug Gialgan Fidia with damaged or opened packaging.

Contraindications

Side effects

Rarely, mild transient soreness, edema, increased exudate in the joint cavity, fever, and redness in the injection area may occur.

The above symptoms are transient and usually disappear after 24 hours. If these symptoms occur, it is recommended to relieve the affected joint and apply ice.

There have been isolated cases of allergic reactions (itching, rash, urticaria) and anaphylactic reactions to the drug.

Pregnancy use

Should not be used in pregnancy, during breastfeeding and in children due to lack of clinical data.

Similarities